Corona Vaccine : Scientists prepared vaccine on MRNA technology, permission for second and third phase trials

 | 
Corona Vaccine : Scientists prepared vaccine on MRNA technology, permission for second and third phase trials

After giving the world's first DNA vaccine, now Indian scientists have prepared the vaccine on mRNA technology. This vaccine has been found to be completely safe during testing in animals. After this, permission has been given for the second and third phase trials of the vaccine.


Corona Vaccine : Scientists prepared vaccine on MRNA technology, permission for second and third phase trials


Currently, the American company Moderna has an mRNA vaccine. This will be the third indigenous vaccine after Covaxin and Jaykov. Work is going on on another indigenous vaccine which is being tested through Biological E company.


An official of the Drug Controller General of India said that after getting the recommendation from the Expert Committee (SEC), pharma company Genova has been allowed to start the second and third phase trials for India's first mRNA vaccine simultaneously.

Corona Vaccine : Scientists prepared vaccine on MRNA technology, permission for second and third phase trials

In the coming days, the vaccine will be tested in 10 to 15 hospitals in the country under the second phase, in which it will be seen whether antibodies are developed after giving the vaccine. Whereas the third phase trial will be done in 22 hospitals of the country and in this trial it will be seen to what extent the antibodies made from the vaccine are successful in preventing infection.

Vaccines found safe on animals

Dr. Renu Swarup, Secretary, Department of Biotechnology (DBT), Government of India, has informed that the research network of DBT and ICMR will also be used for testing on this vaccine. This vaccine has been found completely safe in testing on animals. At present, it is named HGCO-19.

Dr. Sanjay Singh, CEO, Genoa Biopharmaceutical Company said that the company has already started focusing on the production of the vaccine. So that it can be brought into supply immediately after the test is completed and emergency use is allowed.